

Reference number(s)
2775-H

SPECIALTY QUANTITY LIMIT PROGRAM

TEGSEDI (inotersen)

I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for the FDA-approved indication fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

II. COVERED QUANTITIES

Medication	Standard Limit	FDA-recommended dosing
Tegsedi (inotersen) 284mg/1.5mL single-dose, prefilled syringe	4 prefilled syringes per 28 days	284 mg administered by subcutaneous injection once weekly.

III. REFERENCES

1. Tegsedi [package insert]. Boston, MA: Akcea Therapeutics, Inc. October 2018.